Focus: Gland Pharma is an India-based specialty pharmaceutical manufacturer focused on small-volume parenterals, operating as a publicly traded company with concentrated revenue from a single blockbuster asset.
Profile data last refreshed 6h ago · AI intelligence enriched 2w ago
No open roles listed right now. Follow Gland Pharma to get notified when they start hiring — the background below is worth knowing for when they do.
Generated by Claude from Gland Pharma's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Flagship NDA generating 99% of company revenue with 15+ years of exclusivity; primary profit engine and sole commercial focus.
Help build intelligence for Gland Pharma
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generic ANDA in pre-launch phase; modest revenue potential but signals portfolio expansion into critical-care antibiotics.
Off-patent ANDA generating minimal revenue; represents legacy portfolio asset in post-exclusivity phase.
Off-patent generic with negligible revenue contribution; critical-care utility but limited differentiation.
Niche antibiotic with minimal revenue; reserve-therapy positioning limits commercial scale.
Off-patent generic supporting oncology and hematology; negligible independent revenue.
Cornerstone oncology drug now off-patent with minimal revenue; subject to active manufacturing delay shortage.
Rare-disease indication with negligible revenue; highly specialized niche with limited market opportunity.
Over-the-counter generic commodity with nominal revenue; indicates portfolio breadth but not value creation.
Off-patent NSAID with no disclosed Part D spending; minor portfolio contributor in mature market segment.
93 discontinued, 155 duplicate formulations not shown
No open positions listed yet. Check their careers page directly.
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/moTwo active drug shortages (Cisplatin, Etomidate) indicate manufacturing or supply-chain stress; cisplatin shortage explicitly attributed to manufacturing delay.
+122 more products